News
EDT Novavax (NVAX) down 10% after WSJ report on FDA request for additional vaccine trialStay Ahead of the Market: Discover outperforming ...
(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results